Drusen are one of the earliest signs of age-related macular degeneration (AMD) and are important for assessing disease progression and for the staging of disease severity. SD-OCT imaging is currently the most reliable strategy for following drusen morphology and progression over time, and SD-OCT imaging has replaced color fundus imaging for following drusen in clinical trials. The SD-OCT algorithm used to measure drusen defines drusen as elevations of the overlying RPE and provides both area and volume measurements. Drusen volume was found to be a more sensitive indicator of drusen growth compared with area measurements and offers an opportunity to study therapies at an earlier stage of AMD. By intervening earlier, there’s the potential to preserve better vision over a lifetime. An ideal baseline drusen volume to study in clinical trials was found to be a drusen volume of at least 0.03 mm3 (cube root volume 0.31 mm), which is easily measured by SD-OCT imaging and includes the large drusen (125 µm) that are easily seen on color fundus imaging. To determine if drusen actually grow or decrease in size, we recommend the use of the difference in cube-root of the volume measurements to evaluate the change in drusen over time.
|Original language||English (US)|
|Title of host publication||Spectral Domain Optical Coherence Tomography in Macular Diseases|
|Number of pages||9|
|State||Published - Jan 1 2016|
ASJC Scopus subject areas